|
What's inside ?
MigraSpray contains only
natural, standardized
ingredients and there have been
no reported side effects and no
reports of interaction with any
over-the-counter or prescription
medications. MigraSpray is safe
for treating migraine attacks
and safe for regular daily use
to prevent the onset of migraine
headache symptoms. There have
been no reports of
Medication Overuse Headache (MOH).
MigraSpray contains the active
ingredients
feverfew
(its primary ingredient),
goldenseal dandelion and larch
agaric. Feverfew has been used
for centuries for the treatment
of a variety of ailments
including headaches, rheumatic
aches, abdominal pain and
menstrual cramps. Studies have
shown that feverfew acts as a
natural anti-inflammatory
controlling the inflammation
that results in cerebral blood
vessel dilation, believed to
cause or contribute to the
symptoms of migraine headaches.
The herb Feverfew (Pyrethrum
Parthenium), also known as
Tanacetum parthenium, is native
to Europe, although it is now
commonly found in many parts of
the world, including North and
South America. Feverfew is a
perennial plant and is
classified as a member of the
Asteracea or Compositea family,
a relative of the daisy.
The active ingredients in
Feverfew are sesquiterpene
lactones, the primary component
being parthenolide, a phyto-chemical.
Studies have shown that
parthenolide inhibits platelet
aggregation and the release of
serotonin from platelets.
Feverfew has also been shown to
inhibit pro-inflammatory
prostaglandin synthesis. These
anti-inflammatory properties may
control the inflammation that
results in cerebral blood vessel
dilation, a cause or contributor
to the symptoms of migraine
headaches.
Feverfew has been used for
centuries and originally became
popular with English herbalists
in the middle ages. As the name
suggests, feverfew was used as
an application for the treatment
of “fevers.” However, the word
“fever” at that time referred to
a number of ailments, including
rheumatic aches, abdominal pain
and headaches.
Over the past two decades
medical interest of feverfew has
been rekindled in response to
various in-vitro studies as well
as the wide spread use of
feverfew among the general
public. A number of research
groups have formally
investigated the clinical use of
the herb for the relief of
symptoms of migraine headaches.
Several studies, including one
in "The Lancet" and another in
"The British Medical Journal"
have demonstrated feverfew’s
potential for preventative
relief of migraine. These
double-blind placebo studies
showed a statistically
significant number of patients
reporting a reduction in the
number and/or severity of
migraine attacks.
Subsequent studies have
substantiated the use of
feverfew in controlling the
symptoms of migraines.
A study testing the efficacy of
using MigraSpray for prevention
was conducted in New York City
by Dr. Fred Pescatore, M.D.,
MPH, Director of the Centers for
Integrative and Complimentary
Medicine in New York City and
Dallas. Of the patients studied
using MigraSpray on a continual
daily basis, approximately 90%
had their migraine headache
attacks eliminated.
The efficacy of MigraSpray for
treating a migraine attack was
also demonstrated in a
randomized, placebo-controlled,
double-blind, crossover trial
for migraine headache relief
drawn from a general population,
reporting migraine headaches.
The strength of this trial
includes its draw from a general
population, design, outside
review, extremely high safety
record, equal baseline
characteristics between the two
groups (placebo and product),
and statistical significance in
all the major end-point
categories. The results of the
trial demonstrated that nearly
eighty-eight percent of the
patients studied using
MigraSpray received some degree
of relief from their migraine
headache symptoms within an
average of less than 7 minutes.
The results of this study are
statistically significant, at a
P value of less than 0.01 in all
parameters. |
